Catalyst Pharmaceuticals Reports Third Quarter 2021 Financial Results
Continued Strong Financial and Operational Performance in the Third Quarter 2021FIRDAPSE® Revenue of $35.9 Million Increased 23.1% Compared to Third Quarter 2020Plans to Seek to Expand the U.S. Approval of FIRDAPSE To Include Pediatric LEMS PatientsStrong Cash Position $174.8 Million Supports Long-term Growth StrategyCompany to Host Quarterly Conference Call on November 10, 2021, at 8:30 AM […]